Biosynthetic Squalene Vaccine Adjuvant Plant Model

Underwrite engineered S. cerevisiae yeast fermentation facilities synthesizing 1,200 tonnes/year of 99.8% pharmaceutical-grade squalene (displacing deep-sea shark liver oil for vaccine adjuvant emulsions and luxury cosmetics). Model pharma off-take ($45/kg), and 20-yr IRR.